Market research
GERN Geron Corporation
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 977M
- P/E ratio
- Not available
- Analyst target
- 4.25
- Dividend yield
- Not available
- Beta
- 0.59
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US3741631036
- Market cap
- 977M
- P/E ratio
- Not available
- Analyst target
- 4.25
- Dividend yield
- Not available
- Beta
- 0.59
About
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the GERN discussion.
5 years, 4 months ago
Geron Corporation is currently in a long term downtrend where the price is trading 17.7% below its 200 day moving average.
From a valuation standpoint, the stock is 29.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1738.2.
Geron Corporation's total revenue sank by 70.8% to $50K since the same quarter in the previous year.
Its net income has increased by 18.2% to $-24M since the same quarter in the previous year.
Finally, its free cash flow fell by 20.8% to $-13M since the same quarter in the previous year.
Based on the above factors, Geron Corporation gets an overall score of 1/5.